PCLOF (PharmaCielo) Net Change in Cash: $-0.03 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PharmaCielo Net Change in Cash?

PharmaCielo PCLOF -8.52% Net Change in Cash is $-0.03 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

PharmaCielo's Net Change in Cash for the three months ended in Mar. 2026 was $-0.20 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.03 Mil.

PharmaCielo Net Change in Cash Historical Data

* Premium members only.

The historical data trend for PharmaCielo's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCielo Net Change in Cash Chart

PharmaCielo Annual Data
Trend Aug17 Aug18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Mar26
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only -2.75 -3.80 -0.08 0.06 -0.03

PharmaCielo Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Mar26
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 -0.04 0.18 0.02 -0.20

PharmaCielo Net Change in Cash Calculation

PharmaCielo's Net Change in Cash for the fiscal year that ended in Mar. 2026 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-3.362+7.297+-3.964+0.001
=-0.03

PharmaCielo's Net Change in Cash for the quarter that ended in Mar. 2026

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-2.719+2.446+0.084+-0.009
=-0.20

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Change in Cash →
What does a Net Change in Cash of $-0.03 Mil mean?
PharmaCielo (PCLOF) has a Net Change in Cash of $-0.03 Mil as of Mar. 2026. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for PharmaCielo and its competitors.
Is PharmaCielo's Net Change in Cash too high?
PharmaCielo's current Net Change in Cash is $-0.03 Mil.
How does PharmaCielo's Net Change in Cash compare to ZTS?
PharmaCielo's Net Change in Cash of $-0.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Change in Cash for a Drug Manufacturers company?
A good Net Change in Cash depends on the Drug Manufacturers industry context. However, Net Change in Cash should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Change in Cash mean?
A high Net Change in Cash can signal that a stock is expensive relative to its fundamentals. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for PharmaCielo and its competitors. PharmaCielo's current Net Change in Cash is $-0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.05, compared to a current price of $0.04 — trading 22.2% below its estimated fair value. The current Net Change in Cash is $-0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Change in Cash calculated?
Net Change in Cash is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current Net Change in Cash is $-0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCielo Business Description

Other Exchanges PCLO:Canada
Address 82 Richmond Street East, Suite 805, Toronto, ON, CAN, M5C 1P1
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.